BSEAccretion Nutraveda Ltd· Pharmaceuticals & BiotechnologyHighNeutral
Announced Fri, 8 May, 2026 · 18:53 IST

Please find enclosed herewith Outcome of Board Meeting dated 08th May, 2026

Revenue Growth 20pctPat Growth 25pctResults View source PDFExplain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
+2.1%Reaction day
₹283.00
prior close
₹250.00
announcement price
After-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used-1.4%+3.5% vs market
Pharmaceuticals peers, median of 158sector-0.4%+2.5% vs sector

On the reaction day the stock moved 3.5 pts more than Nifty Microcap 250 and 2.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
+0.0
10m
+0.0
15m
+0.0
30m
+0.0
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
+2.1-1.4+3.5-0.4+2.5
Next day
-2.9-4.5+1.5-1.9-1.0
2d
—-3.8—-2.6—
3d
-7.8-3.6-4.2-2.1-5.7
4d
-3.9-3.9+0.0-2.0-1.9
5d
-8.1-5.2-2.9-2.6-5.5
1w
-7.1-4.2-2.8-1.5-5.6
15d
—-1.5—-1.9—
1m
-9.2-3.1-6.1-1.3-7.8
2m
-8.4+6.4-14.8+4.2-12.6
3m
—+8.3—+6.1—
UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 158Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Accretion Nutraveda Ltd reported strong FY 2025-26 audited results with revenue growing 110% to Rs 3,360.31 Lakhs from Rs 1,600.18 Lakhs. PAT surged 103% to Rs 506.83 Lakhs from Rs 250.09 Lakhs, with EPS of Rs 9.35 vs Rs 6.88. The company received an unmodified (clean) audit opinion from VSSB & Associates. The board saw significant changes: two independent directors (Arun Dash and Mahipal Singh Chouhan) resigned citing personal/professional commitments, while two new independent directors (Chand Rameshbhai Kanabar and Ms. Grishma A Shewale) were appointed. New secretarial auditors (Sakhiya & Co.) and internal auditors (UMT & Co.) were appointed. The company also listed on BSE SME in February 2026 via IPO raising Rs 2,476.80 Lakhs, with Rs 1,821.32 Lakhs utilized so far.

Likely market impact

The company delivered exceptional revenue and profit growth following its recent IPO listing. However, negative operating cash flow of Rs 2,278.43 Lakhs despite high profitability warrants attention. The simultaneous resignation of two independent directors may raise governance concerns despite clean auditor opinion.